Shionogi links with Quark in osteoarthritis deal:
This article was originally published in Clinica
US company Quark Biotech has linked in a research and licensing agreement with Shionogi of Japan to discover, identify, and determine the function of genes associated with osteoarthritis. Osaka-based Shionogi plans to develop and manufacture candidate diagnostic products for the disease using the information. It will have exclusive marketing rights in Japan and Asia to any products resulting from the deal. The company, whose main focus is pharmaceuticals, also expects to gain experience in discovery-related genomics and bioinformatics. The two companies will share co-marketing rights in the rest of the world. San Ramon, California-based Quark claims to have a comprehensive portfolio of genomic technologies and bioinformatics systems.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.